相关实验视频

Updated: Jun 25, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

基于机器学习的集成开发了一种免疫细胞死亡衍生 lncRNA 签名,用于预测肺腺癌的预后和免疫治疗反应

Jiazheng Sun¹, Hehua Guo^1,2, Siyu Zhang¹

¹Department of Respiratory Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Scientific reports

|May 22, 2024

概括

这项研究引入了一种新的长非编码RNA (lncRNA) 签名,用于预测肺腺癌的预后和免疫治疗反应. 该签名提供稳定的性能,并指导化疗药物选择.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

长非编码RNAs (lncRNAs) 在调节瘤免疫微环境和早期癌症发展方面发挥作用.
免疫细胞死亡 (ICD) 涉及释放瘤抗原和危险信号,刺激抗瘤免疫反应.
与ICD相关的lncRNAs在肺腺癌预后和免疫治疗中的作用仍未得到充分研究.

研究的目的:

研究肺腺癌中与瘤免疫细胞死亡相关的长非编码RNA (lncRNAs) 的预后和预测价值.
开发和验证一种新的 lncRNA 签名,用于预测患者的治疗结果和免疫治疗的好处.

主要方法:

利用了来自癌症基因组图集 (TCGA) 和基因表达总汇 (GEO) 数据库的肺腺癌队列.
应用机器学习算法来开发一种免疫性细胞死亡指数 (ICDI) 签名.
验证了该签名在预测多个癌症队列的预后和免疫治疗反应方面的表现.

主要成果:

开发了一个稳定和强大的ICDI签名用于肺腺癌.
与现有签名相比,ICDI签名表现出优越的预后性能.
该签名显示了免疫治疗对肺腺癌和其他癌症的益处的预测价值.
签名还为化学疗法药物使用提供了指导.

结论:

开发的ICDI签名是预测肺腺癌的预后和免疫治疗反应的宝贵工具.
这种特征对预测各种癌症类型的免疫疗法益处具有更广泛的意义.
这些发现支持ICD相关的lncRNAs作为个性化癌症治疗和治疗选择的生物标志物的潜力.

关键词:

免疫原性细胞死亡免疫治疗是一种免疫疗法.这是一个LncRNARNA.肺部腺癌瘤是肺部腺癌.预测签名的预测签名

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.